Implementation of the anemia guidelines

被引:3
作者
DeOreo, PB
Eschbach, JW
机构
[1] Ctr Dialysis Care Cleveland, Cleveland, OH USA
[2] Minor & James Med, Seattle, WA USA
来源
ADVANCES IN RENAL REPLACEMENT THERAPY | 1999年 / 6卷 / 01期
关键词
anemia; renal failure; guidelines; implementation; barriers;
D O I
10.1016/S1073-4449(99)70004-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Implementation of the National Kidney Foundation-Dialysis Outcomes Quality Initiative (NKF-DOQI) Guidelines for the treatment of the anemia of chronic renal failure is a great challenge to all concerned with the improvement in the quality of life and survival of patients with chronic renal failure. These include physicians, nurses, technicians, dietitions, social workers, administrators, and private and public (Health Care Financing Administration) payers of the care. The principles of the process of implementation are reviewed and the barriers that can prevent implementation are discussed, showing how most of these can be overcome. Several of the more controversial Guidelines are discussed in detail, showing that with protocols that address the means for implementation, the goals of these Guidelines can be achieved. (C) 1999 by the National Kidney Foundation, Inc.
引用
收藏
页码:18 / 27
页数:10
相关论文
共 12 条
[1]  
[Anonymous], 1997, Am J Kidney Dis, V30, pS192
[2]  
CHURCHILL DN, 1995, CLIN NEPHROL, V43, P184
[3]   IMPLEMENTATION OF A CONTINUOUS QUALITY IMPROVEMENT PROCESS IN A FREESTANDING HEMODIALYSIS UNIT [J].
DEOREO, PB .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 24 (02) :355-361
[4]   THE ANEMIA OF CHRONIC RENAL-FAILURE - PATHO-PHYSIOLOGY AND THE EFFECTS OF RECOMBINANT ERYTHROPOIETIN [J].
ESCHBACH, JW ;
BOURDEAU, J ;
COE, F ;
TOBACK, G ;
COHEN, JJ ;
POCHEDLY, C ;
GARELLA, S ;
LAU, K ;
BUSHINSKY, D ;
SPRAGUE, S ;
KUMAR, S ;
SACKS, P ;
KATHPALIA, S ;
RICHTER, M ;
MADIAS, NE ;
HARRINGTON, JT .
KIDNEY INTERNATIONAL, 1989, 35 (01) :134-148
[5]   RECOMBINANT HUMAN ERYTHROPOIETIN IN ANEMIC PATIENTS WITH END-STAGE RENAL-DISEASE - RESULTS OF A PHASE-III MULTICENTER CLINICAL-TRIAL [J].
ESCHBACH, JW ;
ABDULHADI, MH ;
BROWNE, JK ;
DELANO, BG ;
DOWNING, MR ;
EGRIE, JC ;
EVANS, RW ;
FRIEDMAN, EA ;
GRABER, SE ;
HALEY, NR ;
KORBET, S ;
KRANTZ, SB ;
LUNDIN, AP ;
NISSENSON, AR ;
OGDEN, DA ;
PAGANINI, EP ;
RADER, B ;
RUTSKY, EA ;
STIVELMAN, J ;
STONE, WJ ;
TESCHAN, P ;
VANSTONE, JC ;
VANWYCK, DB ;
ZUCKERMAN, K ;
ADAMSON, JW .
ANNALS OF INTERNAL MEDICINE, 1989, 111 (12) :992-1000
[6]  
ESCHBACH JW, 1989, ANN NY ACAD SCI, V554, P225
[7]  
EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P825
[8]   The safety of intravenous iron dextran in hemodialysis patients [J].
Fishbane, S ;
Ungureanu, VD ;
Maesaka, JK ;
Kaupke, CJ ;
Lim, V ;
Wish, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (04) :529-534
[9]  
Leider HL, 1998, AM J MANAG CARE, V4, P583
[10]   CLINICAL PHARMACOKINETICS OF EPOETIN (RECOMBINANT-HUMAN-ERYTHROPOIETIN) [J].
MACDOUGALL, IC ;
ROBERTS, DE ;
COLES, GA ;
WILLIAMS, JD .
CLINICAL PHARMACOKINETICS, 1991, 20 (02) :99-113